Designing Paclitaxel Drug Delivery Systems Aimed at Improved  Patient Outcomes: Current Status and Challenges

<table>Time courses of paclitaxel levels in tumor of murine B16 melanoma-induced mice after i.v. administration of 50 mg/kg dose of Genexol-PM (<i>◆</i>) and 20 mg/kg dose of Taxol (<i>▾</i>). Each point represents the mean ± S.D. of four mice per time point (reproduced with permission from Kim et al., [<a href="/journals/isrn/2012/623139/#B3">3</a>]).</table>

International Scholarly Research Notices

fig16

Figure 16

Figure 16: Designing Paclitaxel Drug Delivery Systems Aimed at Improved  Patient Outcomes: Current Status and Challenges 